Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

215
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
215

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishing In Vitro Models of Dorsal Root Ganglia Culture: Complementary Approaches for Investigating Cancer-Nerve Crosstalk.

Journal of visualized experiments : JoVE·2025
Same author

Cellular mechanisms of RET receptor dysfunction in multiple endocrine neoplasia 2.

Endocrine-related cancer·2024
Same author

Loss of tumor suppressor TMEM127 drives RET-mediated transformation through disrupted membrane dynamics.

eLife·2024
Same author

TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation.

Cell reports·2023
Same author

Loss of Tumour Suppressor TMEM127 Drives RET-mediated Transformation Through Disrupted Membrane Dynamics.

bioRxiv : the preprint server for biology·2023
Same author

Evaluating Cell Membrane Localization and Intracellular Transport of Proteins by Biotinylation.

Methods in molecular biology (Clifton, N.J.)·2022

Related Experiment Video

Updated: Aug 2, 2025

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model
07:43

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Published on: August 5, 2021

2.0K

Selpercatinib: First approved selective RET inhibitor.

Larissa C B Oliveira1, Lois M Mulligan1

  • 1Division of Cancer Biology and Genetics, Cancer Research Institute, and Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, K7L 3N6, Canada.

Cell
|April 14, 2023
PubMed
Summary

Selpercatinib, a novel RET inhibitor, effectively targets RET fusion proteins and mutants. This FDA-approved therapy blocks cancer cell proliferation and survival signals, offering new hope for targeted cancer treatment.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K

Related Experiment Videos

Last Updated: Aug 2, 2025

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model
07:43

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Published on: August 5, 2021

2.0K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The RET proto-oncogene plays a critical role in various cancers when altered by fusions or mutations.
  • Targeting RET signaling pathways is a promising strategy for cancer therapy.

Purpose of the Study:

  • To introduce Selpercatinib, a potent and selective RET kinase inhibitor.
  • To highlight its mechanism of action in inhibiting oncogenic RET alterations.

Main Methods:

  • Selpercatinib binds to the RET kinase active site.
  • It inhibits constitutively dimerized RET fusion proteins and activated point mutants.

Main Results:

  • Selpercatinib effectively blocks downstream signals essential for cancer cell proliferation and survival.
  • It represents a significant advancement in targeted cancer therapy.

Conclusions:

  • Selpercatinib is the first FDA-approved drug for tumor-agnostic targeting of oncogenic RET fusion proteins.
  • This selective RET inhibitor offers a new therapeutic option for patients with RET-altered cancers.